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Background: Human malaria parasite infection and its control is a global challenge which is responsible for ~0.65
million deaths every year globally. The emergence of drug resistant malaria parasite is another challenge to fight
with malaria. Enormous efforts are being made to identify suitable drug targets in order to develop newer classes
of drug. Helicases play crucial roles in DNA metabolism and have been proposed as therapeutic targets for cancer
therapy as well as viral and parasitic infections. Genome wide analysis revealed that Plasmodium falciparum
possesses UvrD helicase, which is absent in the human host.
Results: Recently the biochemical characterization of P. falciparum UvrD helicase revealed that N-terminal UvrD
(PfUDN) hydrolyses ATP, translocates in 3’ to 5’ direction and interacts with MLH to modulate each other’s activity.
In this follow up study, further characterization of P. falciparum UvrD helicase is presented. Here, we screened the
effect of various DNA interacting compounds on the ATPase and helicase activity of PfUDN. This study resulted into
the identification of daunorubicin (daunomycin), netropsin, nogalamycin, and ethidium bromide as the potential
inhibitor molecules for the biochemical activities of PfUDN with IC50 values ranging from ~3.0 to ~5.0 μM.
Interestingly etoposide did not inhibit the ATPase activity but considerable inhibition of unwinding activity was
observed at 20 μM. Further study for analyzing the importance of PfUvrD enzyme in parasite growth revealed that
PfUvrD is crucial/important for its growth ex-vivo.
Conclusions: As PfUvrD is absent in human hence on the basis of this study we propose PfUvrD as suitable drug
target to control malaria. Some of the PfUvrD inhibitors identified in the present study can be utilized to further
design novel and specific inhibitor molecules.
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Human malaria is the parasitic disease caused by five dif-
ferent species of Plasmodium (Plasmodium falciparum,
P. vivax, P. ovale, P. malarie and P. knowlesi), among
them P. falciparum is responsible for the most severe
and lethal infection (reviewed by [1]). There is contro-
versy over the number of human deaths due to malaria
but as per WHO report malaria is responsible for ~0.65
million deaths every year [2,3]. The efforts to identify
suitable drug targets to fight with malaria parasite infec-
tions are a global concern [1,4] as many previous attempts* Correspondence: renu@icgeb.res.in
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unless otherwise stated.have been unsuccessful to develop new class of antimalar-
ial drugs. Similarly the attempts to develop vaccine for
malaria are not very promising and a vaccine for malaria is
not possible in near future [2,5,6]. There are certainly lim-
ited drugs available for treatment of malaria that includes
chloroquine, sulphadoxine, pyrimethamine and deriva-
tives. During the last few years the situation has worsened
mainly due to the emergence of malaria parasite resistant
to several anti-malarial drugs and their spread in other
region of the world [7-9]. Thus it is equally important
to explore the underlying cause of the emergence of
drug resistant parasite and development of novel thera-
peutics to treat the resistant malaria parasite infections.
Although many putative therapeutic targets for malaria
have been reported in the recent past [10-19] butLtd. This is an Open Access article distributed under the terms of the Creative
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for the successful development of suitable drugs. Helicases
have also been proposed as suitable drug targets for
human cancers as well as many pathogens including
viruses and P. falciparum [20-33].
Helicases are molecular motor proteins that play im-
portant roles in the metabolism of nucleic acids. It is
well established that in-vivo each helicase is specialized
for its own helicase activity led biochemical role. The
genome wide analysis of P. falciparum helicases re-
vealed that the parasite contains a UvrD helicase while
this enzyme is absent in human host [34,35]. Later, the
biochemical characterization of this P. falciparum spe-
cific UvrD helicase revealed its characteristic biochemical
activities [32].
UvrD helicase has been characterized from Escherichia
coli and Mycobacterium tuberculosis [36-38] and it is a
critical component of the DNA repair process of prokary-
otes. In particular, UvrD is required for the mismatch
repair (MMR) and nucleotide excision repair (NER) to
repair mismatches occurring during replication or DNA
lesions such as UV-induced pyrimidine dimers or more
bulky adducts [35,39,40]. In a recent study we have re-
ported the detailed biochemical characterization of the
UvrD helicase from P. falciparum and have shown that
it exhibits the ssDNA-dependent ATPase activity and
the DNA helicase activity in 3’ to 5’ direction [32,33,35].
Recent study on UvrD in different Plasmodium species
revealed that the other species of Plasmodium also contain
putative UvrD helicase [33].
Here, in the follow up study of our previous work
[32], we report the effect of different DNA interacting
compounds (actinomycin, camptothecin, ciprofloxacin,
cisplatin, cyclophosphamide, DAPI, daunorubicin, etopo-
side, ethidium bromide, genistein, morin, netropsin, noga-
lamycin and novobiocin) on the helicase and ATPase
activities of PfUvrD helicase. Out of all these molecules
tested, only daunorubicin, ethidium bromide, netropsin,
and nogalamycin were found to be potent inhibitors
for the PfUDN enzymatic activities. The inhibition of
PfUvrD by dsRNA showed that it is required for the
ex-vivo intraerythrocytic development of the parasite
P. falciparum 3D7. This study will set the stage for de-
signing the specific inhibitors for inhibiting the enzym-
atic activity of PfUDN which in turn will block the
parasite growth as well.
Methods
Materials
Nucleoside triphosphates and deoxynucleoside triphos-
phates were obtained from Pharmacia (Uppsala, Sweden)
and [γ-32P] ATP was purchased from Perkin Elmer
(Boston, MA, USA). M13mp19 ssDNA was purchased
from Invitrogen (Carlsbad, CA, USA). Synthetic DNAoligonucleotides were synthesized chemically. The DNA-
interacting compounds, camptothecin, ciprofloxacin, cis-
platin, DAPI, daunorubicin, etoposide and morin were
purchased from Topogene Inc. (Columbus, OH, USA).
Cyclophosphamide, genistein, netropsin, nogalamycin
and novobiocin were obtained from Sigma Chemical Co.
(St Louis, MO, USA), ethidium bromide and actinomycin
was obtained from BDH (E. Merck, Mumbai, India) and
Boehringer Mannheim (Indianapolis, IN, USA), respect-
ively. All of these compounds were dissolved in dimethyl-
sulfoxide (DMSO) and stored at 4°C in the dark.
DNA dependent ATPase assay
Standard protocol of ATPase assay was followed as de-
scribed in the previous report [32,41]. The hydrolysis of
ATP catalyzed by PfUDN was assayed by measuring the
formation of Pi from [γ-32P] ATP. The reaction mixture of
10 μl contained [γ-32P] ATP (specific activity 222 TBq.
mmol−1) and cold ATP (1 mM), ATPase buffer (20 mM
Tris-HCl, pH 8.0, 8 mM DTT, 1.0 mM MgCl2, 20 mM
KCl and 16 μg/ml BSA), purified PfUDN and 50 ng or 100
ng of M13 mp19 ssDNA. The reaction mixtures were in-
cubated at 37°C for 60 min. This was followed by thin
layer chromatography (TLC), and the quantitation was
done using Alpha Imager-EP/Image-J software (http://
rsbweb.nih.gov/ij/). In order to study the effect of various
compounds on ssDNA-dependent ATPase activity, differ-
ent compounds were added into the reaction mixture
prior to the addition of the PfUDN. In another set of
experiment, PfUDN was pre-incubated (15 min) with
these compounds in order to obtain the insight of inhibi-
tory mechanism. All the experiments were performed at
least two times and quantification data was used to calcu-
late the standard deviation using Microsoft Excel 2010
and mean value was used to prepare the graph.
Preparation of substrate and DNA helicase assay
Helicase assay was demonstrated using the purified frac-
tion of PfUDN. The specially designed partial duplex
substrate consisted of a 32P-labelled 47-mer DNA oligo-
deoxynucleotide annealed to M13mp19 phage ssDNA.
This oligodeoxynucleotide of the nucleotide sequence
5'- (T)15GTTTTCCCAGTCACGAC(T)15-3' contains 15
base-pairs of non-complementary region (T)15 at both
the 5’ and 3’ ends. Oligodeoxynucleotide was labeled at
5′-end with T4 polynucleotide kinase (PNK) (5U) (New
England Biolabs) and 1.85 MBq of [γ-32P] ATP (specific
activity 222 TBq/mmol) at 37°C for one hour and then
annealed using standard annealing buffer (20 mM Tris-
HCl, pH 7.5, 10 mM MgCl2, 100 mM NaCl, 1 mM DTT)
with 0.5 μg of single-stranded circular M13mp19 (+)
phage DNA by heating at 95°C for 1 min and then trans-
ferring immediately to 65°C for 2 min and then slow cool-
ing to room temperature. Using gel filtration through a
Figure 1 Effect of various compounds (20μM) on the ATPase
activity. A. ATPase assay using DNA preincubated with the
compounds. B. ATPase assay using protein preincubated with the
compounds. Percent ATPase activity of PfUDN in the presence of
various compounds is presented in the bar diagram corresponding
to the autoradiogram. Lane C is no enzyme control, lane UDN is
control reaction of PfUDN without the addition of compound. Lanes
1-14 are the ATPase reactions with enzyme in the presence of different
compounds labeled below the autoradiogram. The position of ATP
and released Pi is shown on the left side of the autoradiogram.
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hybridized oligodeoxynucleotide was removed [32]. The
reaction volume of 10 μl containing the 32P-labeled heli-
case substrate (1000 cpm/10 μl) in appropriate buffer
(20 mMTris-HCl, pH 8.0, 8 mM DTT, 1.0 mM MgCl2,
20 mMKCl and 16 μg/ml BSA) and PfUDN was incu-
bated at 37°C for 60 min. The substrate and products
were separated by electrophoresis on a nondenaturing
12% PAGE and the gel was exposed to hyper film for
autoradiography or scanned on phosphoimager. In order
to study the effect of DNA-interacting compounds on
helicase activity, different compounds were added to the
helicase reaction mixture prior to the addition of the
PfUDN helicase. All the experiments were performed in
duplicate and quantitation of both the substrate and
unwound DNA bands was done using AlphaImager-EP/
Image-J software (http://rsbweb.nih.gov/ij/). Quantifica-
tion data was used to calculate the standard deviation
using Microsoft Excel 2010 and mean value was used to
prepare the graph.
Double stranded (ds) RNA preparation
The clone of PfUDN in the pGEMT easy vector of
Promega (Madison, WI, USA) was used as a template to
amplify the gene, using T7 and SP6 primers [42]. Similarly
the clone of GFP into pGEMT easy vector was used as
control. The PCR products using these two primers
were purified using the Wizard DNA clean-up system
from Promega. These purified templates were used for
in vitro transcription to generate sense RNA (sRNA) and
anti-sense RNA (asRNA) using T7 and the SP6 RiboMAX
Express large-scale RNA production system from Pro-
mega. For the production of dsRNA, equal amounts of
sRNA and asRNA were mixed and incubated at 65°C
for 30 min, and then the incubation was continued at
room temperature overnight. The mixture was treated
with DNase and precipitated after phenol/chloroform
extraction. The pellet of dsRNA was dissolved in diethyl
pyrocarbonate water and treated with RNase T1. These
samples were checked on 1% (w⁄v) native agarose gel.
This dsRNA was quantitated and used for the following
experiments.
Parasite proliferation assay in presence of dsRNA
targeted to UvrD helicase
For analyzing the effect of dsRNA, the cultures were
adjusted to 4% hematocrit with 1% infected red blood
cells (RBCs). 200 μl of this mixture was centrifuged at
1500xg in a Sorvall RT7 centrifuge (Du Pont, Newtown,
CT, USA), and the pellet was resuspended in 50 μl of
incomplete medium and 20 μg dsRNA per ml was
added to this mixture. This mixture was incubated at
37°C with intermittent mixing to avoid settling of RBCs.
After this incubation, serum was added to a finalconcentration of 20% and the mixture was dispensed in
96-well plates and incubated at 37°C for specific times.
The smears were made at different intraerythrocytic
developmental stage of the parasite and the effect was
determined by microscopic examination as well as cyber
green based assay [43]. The parasite proliferation assay
was performed in duplicate and quantification data
(using ELISA reader) was used to calculate the standard
deviation using Microsoft Excel 2010 and mean value
was used to prepare the bar diagram.
Figure 2 (See legend on next page.)
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Figure 2 Analysis of ATPase inhibition kinetics. Concentration curves of compounds A. Netropsin, B. Daunorubicin, C. Nogalamycin, D.
ethidium bromide and E. Ciprofloxacin. In each panel, the autoradiogram of the assay is shown on the left and the quantitative data on the right
side. Lane C in all the panels is control without enzyme and lane 1 in all the panels is reaction with enzyme without the addition of any
compound. Lanes 2–8 are reactions with enzyme in the presence of 0.2, 0.5, 1, 2, 3, 4 and 5 μM compounds labeled below the autoradiogram.
Inhibition kinetics of ciprofloxacin was performed using 0.5-30 μM concentration. The position of ATP and released Pi is shown on the left side of
the autoradiogram.
Table 1 Comparison of inhibitory potential for ATPase
activity
Compounds PfUDN PfH45 PfD66/PfDDX19 PfDH60
Ciprofloxacin 9.9 ND ND ND
Ethidium bromide 3.1 1.5 1.5 2.5
Daunorubicin 4.4 5.0 ND 3.0
Netropsin 3.1 1.5 1.0 3.0
Nogalamycin 3.3 0.8 3.2 0.5
ND- Not determined.
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Effect of various compounds on ssDNA-dependent
ATPase activity
The effect of different compounds (20 μM) on the
ssDNA dependent ATPase activity of PfUDN (100 nM)
was studied using the protocol described in the material
and methods. In the first set of experiment (Figure 1A),
reaction mixture was preincubated (15 min) with the
compounds (20 μM) and then PfUDN was added to
the mixture. The results clearly show that ciprofloxacin,
morin, nogalamycin, netropsin, daunobrubicin, ethidium
bromide and DAPI, (Figure 1A, lanes 3, 9-14 respectively)
inhibit the ssDNA dependent ATPase activity of PfUDN
under these conditions. Among these compounds, which
inhibited the ATPase activity, nogalamycin, daunorubicin,
netropsin, and ethidium bromide are the top four inhib-
itors of ATPase activity at 20 μM concentration. Cipro-
floxacin and morin weakly inhibit the ATPase activity of
PfUDN (Figure 1A, lanes 3 and 9, respectively). The
other compounds like novobiocin, camptothecin, cis-
platin, cyclophosphamide, etoposide, actinomycin, and
genistein were not able to considerably inhibit the
ssDNA dependent ATPase activity of PfUDN at 20 μM
concentration (Figure 1A, lanes 1, 2 and 4-8, respect-
ively). In the second set of experiment, PfUDN was pre-
incubated with the compound (15 min) then the reaction
mixture was added. The results show that the intensity of
inhibition was considerably decreased (Figure 1B, lanes 3,
9-14 respectively). Thus from these observations it seems
that these compounds (daunorubicin, netropsin, nogala-
mycin, ethidium bromide, morin and ciprofloxacin) poten-
tially inhibited the ATPase activity possibly by interfering
with the DNA binding of PfUDN protein. To get further
insight another assay was performed with fixed concentra-
tion of inhibitor molecule but in the presence of 100 ng of
ssDNA in the reaction and the results show that inhibition
was slightly less as compared to the reactions containing
50 ng ssDNA in the reaction (Additional file 1: Figure S1).
These compounds (daunorubicin, netropsin, nogalamycin,
ethidium bromide and ciprofloxacin) were further used
for the study of kinetics of inhibition of PfUDN ATPase
activity. Increasing concentration of inhibitors (0.2 to
5.0 μM) was used in the ATPase reaction (Figure 2A-2D,
lanes 1-8 in each panel) and the results show that the
effective inhibitors are netropsin, daunorubicin, nogala-
mycin and ethidium bromide with IC50 value rangingfrom ~3.0 to ~4.5 μM, respectively (Figure 2A-2D)
(Table 1). It is interesting to note that ciprofloxacin was
effective only at higher concentration and the IC50 value for
ciprofloxacin is ~10.0 μM (Figure 2E, lanes 2-8) (Table 1).
Effect of various compounds on DNA helicase activity of
PfUDN
The DNA helicase or unwinding activity of PfUDN in the
presence of 20 μM of different compounds was tested sep-
arately by using the partial duplex substrate. This duplex
substrate used in the helicase reaction, has 15 mer over-
hangs (i.e. non complementary region) on both the 5’ and
3’ends and 17 nucleotide region annealed with the circular
DNA. The results obtained clearly show that all the com-
pounds which inhibited the ATPase activity i.e. ciprofloxa-
cin, nogalamycin, netropsin, daunorubicin and ethidium
bromide also inhibit the DNA unwinding activity of
PfUDN effectively with different strength (Figure 3, lanes
4, and 11-14 respectively). Interestingly etoposide, which
does not inhibit the ATPase activity, blocks the helicase
activity appreciably at 20 μM under in vitro conditions
(Figure 3, lane 7). Whereas the other nucleic acid binding
agents like novobiocin, camptothecin, cisplatin, cyclophos-
phamide, actinomycin, genistein and morin were not able
to considerably inhibit the DNA unwinding activity of
PfUDN in in vitro conditions (Figure 3, lanes 2, 3, 5, 6, 8-
10, respectively). These inhibitor molecules (daunorubicin,
netropsin, nogalamycin and ethidium bromide) were
further used for the kinetic study of helicase activity of
PfUDN.
The concentration of inhibitors used in unwinding re-
action of PfUDN ranged from 0.5-5.0 μM and the results
show clearly that the effective inhibitor is daunorubicin
with IC50 value of ~3.0 μM (Figure 4C, lanes 2-7)
(Table 2), followed by other inhibitors such as nogalamycin
Figure 3 The effect of different compounds on the DNA unwinding activity of PfUDN. The structure of the DNA helicase substrate is shown on
the left side of the autoradiogram of the gel. Lane C is the control without enzyme and lane B is heated substrate. Lane 1 is the control reaction with
enzyme without any added compound. Lanes 2–14 are the reactions with enzyme in the presence of different compounds (20 μM) labeled
below the autoradiogram. Percent helicase activity of PfUDN in presence of various compounds are presented in the bar diagram corresponding to
the autoradiogram.
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ethidium bromide (Figure 4D, lanes 2-7) with IC50 values
ranging from ~3-5 μM, respectively (Table 2). Thus these
results clearly show that these four compounds have poten-
tial to inhibit the helicase activity of PfUDN. Although eto-
poside and ciprofloxacin inhibited the helicase activity at
higher (20 μM) concentration but these compounds failed
to show appreciable inhibition upto 5 μM concentration
tested (data not shown).
Inhibition study of parasite growth by PfUDN ds-RNA
Previously it has been shown that dsRNA based knock-
down of gene(s) worked effectively at least for the DNA
helicases of P. falciparum [42]. The P. falciparum 3D7
culture was treated with PfUDN dsRNA (Figure 5A)
(20 μg/ml) in synchronized culture and the dsRNA of
green fluorescent protein (GFP) gene was used as con-
trol in this study. It is interesting to note that the para-
site growth was inhibited ~40% (at 56 hour stage i.e.
ring stage) by the addition of PfUDN dsRNA in culture
(Figure 5B lane 2). The treated as well as control culture
was monitored at different time interval at all the develop-
mental stages using Giemsa staining. The result of control
experiments (Figure 5C (i) in a-d), revealed that the
morphology of the parasite developmental stage is almost
normal. The morphology of the parasite is less distorted
after the treatment with PfUDN dsRNA alone during ring
and trophozoite stage (Figure 5C (ii) in a and b), whileduring the late trophozoite to schizont stages considerable
inhibition was noticed at both first and second cycle of
asexual development (Figure 5C (ii) in c and d). The re-
sults clearly show that PfUDN dsRNA inhibits the para-
site growth especially during early schizont stage, which
is evidenced from morphological changes during ex-vivo
growth of the parasite. It seems that proper nuclear div-
ision during schizont stage is hampered in the PfUDN
dsRNA treated cultures and punctate nuclei of schizont
stage were rare as compared to the control experiment.
Parasitemia at schizont stage of the second cycle was
roughly ~8% in control experiment (GFP-dsRNA treated)
while parasitemia decreases to 4-5% in PfUDN-dsRNA
treated culture. Interestingly, most of the UDN-dsRNA
treated parasites were in stress and did not show punctate
nuclei at 94 hour stage (schizonts of second cycle). The
inhibition of the parasite growth was more prominent
at 94-95 hour (second cycle) compared to the 45-46
hour of parasite development (Figure 5C (ii) in d).
Discussion
The identification of suitable drug target and newer class
of antimalarial drugs has been a challenging task for the
parasitologist worldwide. In order to consider a parasite
protein as a drug target, it should be parasite specific
and importantly essential for the parasite growth. In
silico data revealed that parasite is unique with respect
to the UvrD helicase as its human host lacks this essential
Figure 4 Analysis of helicase inhibition kinetics. Concentration curves of compounds A. netropsin, B. nogalamycin, C. daunorubicin, and D.
ethidium bromide. In each panel, the autoradiogram of the assay is shown on the left and the quantitative data on the right side. Lane C in all
the panels is control without enzyme and lane B in all the panels is heated substrate. Lanes 1-7 are reactions with enzyme in the presence of 0,
0.5, 1, 2, 3, 4 and 5 μM of compounds labeled below the autoradiogram.
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is required to firmly establish whether PfUvrD is essential
for the malaria parasite growth. Interestingly PfUDN inter-
action with PfMLH, a crucial MMR protein, and their
interplay to regulate each other activity points toward the
importance of PfUvrD for the malaria parasite. On the
basis of these observations, PfUvrD is expected as crucialTable 2 Comparison of inhibitory potential for helicase
activity
Compounds PfUDN PfH45 PfD66/PfDDX19 PfDH60
Ethidium bromide 4.8 1.0 1.0 1.5
Daunorubicin 3.0 1.5 ND 0.3
Netropsin 4.7 0.5 0.5 1.2
Nogalamycin 3.5 0.5 5.0 2.0
ND- Not determined.helicase for the parasite’s intraerythrocytic developments
and was proposed as suitable drug target to combat with
dreaded infections of malaria parasite. dsRNA based in-
hibition study suggests that UvrD is an important enzyme
and seems crucial for the successful nuclear division
during early schizont stages of P. falciparum. Although,
mechanism of action of dsRNA is not yet explored and
has been controversial in these parasites [44-48].
In order to find the molecules which block the biochem-
ical activities (ATP hydrolyzing and DNA unwinding ac-
tivities) of PfUvrD, screening with various compounds
including DNA interacting compounds was done in this
study. The results of this study revealed that daunorubicin
inhibited both ATPase and DNA unwinding or helicase
activity of PfUDN with IC50 value of ~3 μM. Daunorubi-
cin or daunomycin belongs to anthracycline family and is
most commonly used as chemotherapeutic for the
Figure 5 Effect of dsRNA on the ex-vivo growth of the Plasmodium falciparum within red blood cells. Parasite growth evaluated by the
SYBER green assay using synchronized cultures. Figure A. shows ds RNA preparation of green fluorescent protein (GFP) (lane 1) and PfUDN (lane
2) lane M is the marker. B. shows the growth of culture 50 hour post dsRNA treatment (i.e. at 56 hour stage of parasite growth) with the dsRNA
of GFP (lane 1 in A), and PfUDN (lane 2 in A). C. Giemsa-stained parasite infected RBC after dsRNA treatment. Control panel in (i) shows the
culture after treatment with GFP-dsRNA while panel (ii) shows the culture after treatment with dsRNA of PfUDN at different time interval as
labeled. The arrows in each panel show P. falciparum infected RBC at different developmental stages.
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lymphocytic leukemia [49]. Similar to the daunorubicin
some other compounds like netropsin, nogalamycin and
ethidium bromide also considerably inhibited the DNA
dependent ATPase activity of PfUDN at low μM concen-
tration. Previously, the effects of daunorubicin, netropsin
and nogalamycin (50μM) have been tested in the parasite
culture (synchronized and unsynchronized) which showed
considerable inhibition of parasite growth (~60-70% inhib-
ition at 72 hour) [42]. Similarly, ciprofloxacin has also
been found effective for the inhibition of malaria parasite
growth [50,51]. Etoposide (VP16) which inhibits DNA un-
winding activity of PfUDN, is clinically active against
Kaposi’s sarcoma, testicular cancer, acute lymphocytic leu-
kaemia and small-cell lung cancer [52]. It was reviewed
that effects of etoposide treatment on P. falciparumparasites showed enhanced cleavage of both nuclear
and apicoplast and the induction of an apoptosis-like
cell death process [52].
The inhibition of the ATPase activity with these com-
pounds was prominent when DNA was preincubated
with inhibitor molecule (Figure 1A versus Figure 1B).
Thus the results indicate that possibly these compounds
interfere with the binding of DNA with PfUDN protein,
which ultimately leads to inhibition of DNA dependent
ATP hydrolysis. Interestingly all these commercially
available molecules, which have been found as inhibitor
for the ATPase activity also inhibit the DNA helicase
activity of PfUDN helicase. Thus this study further
suggests that energy from the ATP hydrolysis is used
as driving force for the DNA unwinding activity. Al-
though, ciprofloxacin inhibited the helicase activity
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appreciably inhibit the activity at lower concentration
(0.5-5 μM). Ciprofloxacin is a fluoroquinolone anti-
biotic, which moderately inhibited the ATPase as well
as helicase activity of PfUDN helicase and it has also
been reported to block the helicase activity of Mcm2-7
helicase [53]. Interestingly, in the present study etopo-
side did not exhibit inhibition on the ATPase activity
of PfUDN but significant inhibition of helicase activity
was observed at 20 μM concentration. Similar to the
ciprofloxacin, etoposide also failed to show appreciable
inhibition of the helicase activity of PfUDN at lower
concentration (0.5-5 μM).
Ethidium bromide is well known DNA intercalating
compound thus it seems that after binding with DNA
this compound blocks the interaction of PfUDN with
DNA and inhibits the ATPase activity led helicase activity.
Although, ethidium bromide cannot be used as drug be-
cause of its properties as potential mutagen but other
inhibitors reported in the present study can be used as
basic molecule to design and synthesize derivatives spe-
cific for the PfUvrD helicase. The concentration at
which these compounds inhibit the ATPase and helicase
activity of PfUDN is certainly not suitable for the thera-
peutics purpose but this study provides a basic idea to
develop novel derivatives in order to achieve significant
inhibition of ATPase and helicase activity of PfUvrD at
much lower concentration. Thus this study will cer-
tainly help pharmacologists to develop derivative of
these drugs specific to the PfUvrD which may result
into significant inhibition at much lower concentration
with the hope to be useful to fight with malaria. Fur-
thermore the knockout out or gene disruption analysis
of PfUvrD is required in order to establish the essentiality
of UvrD for the parasite, P. falciparum but the results of
present study with dsRNA targeted to N-terminal of UvrD
at least indicates that PfUvrD is crucial for parasite and its
growth is inhibited considerably during early schizont
stages of asexual life cycle.
Conclusions
In previous studies we reported the detailed biochem-
ical characterization of malaria parasite Plasmodium
falciparum specific UvrD helicase [32]. The biochemical
studies revealed that PfUvrD exhibits the ATPase as
well as DNA helicase activity. It unwinds DNA duplex
in 3’-5’ direction and interacts with PfMLH to regulate
each other biochemical activities [32]. Recently, we have
also reported that the genetically engineered synthetic
UvrD helicase (appreciably shorter than native PfUvrD)
also showed ATPase and helicase activity [54]. In this
study, we have identified daunorubicin, ethidium brom-
ide, netropsin, and nogalamycin as potent inhibitors for
the PfUDN enzymatic activities. The results furthershow that PfUvrD is crucial for the parasite survival as
its dsRNA showed inhibition of intraerythrocytic devel-
opment of the parasite P. falciparum 3D7 strain. This
study strengthens the speculation that PfUvrD can serve
as suitable drug target to control the malaria. Findings
of this work can be used for designing the specific inhibi-
tors for PfUvrD, which may result into specific inhibition
of UvrD and in turn the parasite growth.
Additional file
Additional file 1: Effect of various compounds (20 μM) on the
ATPase activity in presence of 100 ng of ssDNA. ATPase assay using
DNA preincubated with the compounds was done. Percent ATPase
activity of PfUDN in the presence of various compounds is presented in
the bar diagram corresponding to the autoradiogram. C is no enzyme
control, lane UDN is control reaction of PfUDN without the addition of
compound. Lanes 1-14 are the ATPase reactions with enzyme in the
presence of different compounds labeled below the autoradiogram.
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